Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 51.80 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 55.16 | Oscillator | Neutral |
| Williams %R (14) | -37.59 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.05 (Hist 0.57) | Oscillator | Strong Buy |
| Average Directional Index (14) | 14.27 (+DI 25.1 / -DI 24.8) | Trend | Neutral |
| EMA 20 | 181.75 | MA | Buy |
| SMA 20 | 180.27 | MA | Buy |
| EMA 50 | 184.90 | MA | Sell |
| SMA 50 | 180.53 | MA | Buy |
| SMA 200 | 175.07 | MA | Strong Buy |
Current price $183.64
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 7, 26 | TD Cowen | upgrade | Hold | Buy |
| Aug 7, 26 | Truist Securities | maintain | Hold | Hold |
| Aug 5, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Jul 14, 26 | Truist Securities | maintain | Hold | Hold |
| Jul 10, 26 | UBS | maintain | Buy | Buy |
| Jul 9, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| May 11, 26 | TD Cowen | maintain | Hold | Hold |
| May 8, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| May 8, 26 | Truist Securities | maintain | Hold | Hold |
FY2025 · 10-K disclosure
Stock news · updated daily
DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.
DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
CWA Asset Management Group LLC grew its stake in DaVita Inc. (NYSE: DVA) by 15.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,064 shares of the company's stock after purchasing an additional 3,574 shares during the period. CWA Asset
DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time.
Counterpoint Mutual Funds LLC lifted its holdings in shares of DaVita Inc. (NYSE: DVA) by 56.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,875 shares of the company's stock after acquiring an additional 18,685 shares during
Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.
In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.
DaVita is rated Buy with a $220 12-month price target, offering 22% upside from current levels. Despite flat industry volumes and Medicare rate headwinds, DVA's aggressive buybacks drive most EPS growth, enhancing per-share value. At $180, DVA trades at 9.4x forward earnings, making buybacks more accretive and capital allocation more effective than at recent highs.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 3.88 | 4.02 | Beat 3.6% | $3.55B |
| May 5, 2026 | 2.41 | 2.87 | Beat 19.1% | $3.42B |
| Feb 2, 2026 | 3.24 | 3.40 | Beat 4.9% | $3.62B |
| Oct 29, 2025 | 3.17 | 2.51 | Miss -20.8% | $3.42B |
| Aug 5, 2025 | 2.70 | 2.95 | Beat 9.3% | $3.38B |
| May 12, 2025 | 1.95 | 2.00 | Beat 2.6% | $3.22B |
TTM vs. 5-year historical average (annual ratios)
| Metric | DVA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 15.8x | 12.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 12.4x | EPS est. 14.82 | Discount |
| Price / Book | -15.5x | 24.9x | Discount |
| Price / Sales | 0.8x | 0.8x | In line |
| EV / EBITDA | 7.9x | 9.0x | In line |
| Return on equity | -123.6% | — | Weak |
| Gross margin | 31.0% | 30.4% | In line |
| Debt / Equity | -14.09 | 23.90 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 1.69 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 24, 2026 | 2026-09-24 16:22:17 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:50 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:44 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:38 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:33 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:27 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:22 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:16 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:10:10 | View |
| 4 | Aug 4, 2026 | 2026-08-04 17:27:36 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 22, 26 | Maughan David Paul | officer: Chief Operating Officer, DKC | F-InKind | 7,501 @ $182.34 | $1.37M |
| Aug 15, 26 | Hollar Jason M. | director | A-Award | 278 | — |
| Aug 15, 26 | Desoer Barbara J | director | A-Award | 278 | — |
| Aug 15, 26 | Schechter Adam H | director | A-Award | 278 | — |
| Aug 15, 26 | Moore Gregory J. | director | A-Award | 278 | — |
| Aug 15, 26 | Pullin Dennis W | director | A-Award | 278 | — |
| Aug 15, 26 | Schoppert Wendy Lee | director | A-Award | 278 | — |
| Aug 15, 26 | Arway Pamela M | director | A-Award | 278 | — |